ES2891174T3 - Péptidos que bloquean el reclutamiento de leucocitos y su uso terapéutico - Google Patents

Péptidos que bloquean el reclutamiento de leucocitos y su uso terapéutico Download PDF

Info

Publication number
ES2891174T3
ES2891174T3 ES15749560T ES15749560T ES2891174T3 ES 2891174 T3 ES2891174 T3 ES 2891174T3 ES 15749560 T ES15749560 T ES 15749560T ES 15749560 T ES15749560 T ES 15749560T ES 2891174 T3 ES2891174 T3 ES 2891174T3
Authority
ES
Spain
Prior art keywords
peptide
amino acid
isolated peptide
peptides
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15749560T
Other languages
English (en)
Spanish (es)
Inventor
Stephen Mark Robbins
Donna L Senger
Jennifer Joy Rahn
Paul Kubes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Cancer Therapeutics Inc
Original Assignee
Arch Cancer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Cancer Therapeutics Inc filed Critical Arch Cancer Therapeutics Inc
Application granted granted Critical
Publication of ES2891174T3 publication Critical patent/ES2891174T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15749560T 2014-02-13 2015-02-13 Péptidos que bloquean el reclutamiento de leucocitos y su uso terapéutico Active ES2891174T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939561P 2014-02-13 2014-02-13
PCT/CA2015/000078 WO2015120536A1 (en) 2014-02-13 2015-02-13 Peptides that block leukocyte recruitment and methods of use

Publications (1)

Publication Number Publication Date
ES2891174T3 true ES2891174T3 (es) 2022-01-26

Family

ID=53774369

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15749560T Active ES2891174T3 (es) 2014-02-13 2015-02-13 Péptidos que bloquean el reclutamiento de leucocitos y su uso terapéutico

Country Status (7)

Country Link
US (3) US9464114B2 (cg-RX-API-DMAC7.html)
EP (1) EP3105245B1 (cg-RX-API-DMAC7.html)
JP (2) JP6673837B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015218198B2 (cg-RX-API-DMAC7.html)
CA (1) CA2939266C (cg-RX-API-DMAC7.html)
ES (1) ES2891174T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015120536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334459B1 (en) * 2015-08-11 2025-12-17 Arch Biopartners, Inc. Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
US11286278B2 (en) * 2018-11-30 2022-03-29 Arch Biopartners, Inc. DPEP-1 binding agents and methods of use
EP4574146A1 (en) 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5629179A (en) 1995-03-17 1997-05-13 Novagen, Inc. Method and kit for making CDNA library
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
WO2000063236A2 (en) * 1999-04-16 2000-10-26 Children's Medical Center Corporation Adhesion modulatory peptides and methods for use
CN1323723C (zh) * 2003-12-26 2007-07-04 上海新世界基因技术开发有限公司 Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
JPWO2006134960A1 (ja) * 2005-06-16 2009-01-08 塩野義製薬株式会社 抗炎症剤のスクリーニング方法
EP3461499A1 (en) * 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
US20100324469A1 (en) * 2007-10-04 2010-12-23 Josai University Corporation Drug product, a method of administrating a vaccine using the drug product, and an apparatus for iontophoresis
US20120210458A9 (en) * 2009-02-27 2012-08-16 Yongwei Cao Isolated Novel Nucleic Acid and Protein Molecules from Corn and Methods of Using Thereof
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding

Also Published As

Publication number Publication date
CA2939266C (en) 2023-10-03
WO2015120536A1 (en) 2015-08-20
AU2015218198A1 (en) 2016-09-29
US20150225459A1 (en) 2015-08-13
AU2015218198B2 (en) 2019-07-11
CA2939266A1 (en) 2015-08-20
JP6994054B2 (ja) 2022-02-03
US11083773B2 (en) 2021-08-10
EP3105245A1 (en) 2016-12-21
EP3105245A4 (en) 2017-07-26
US20170072006A1 (en) 2017-03-16
JP6673837B2 (ja) 2020-03-25
JP2017508734A (ja) 2017-03-30
US20200038473A1 (en) 2020-02-06
JP2020055873A (ja) 2020-04-09
EP3105245B1 (en) 2021-08-18
US9464114B2 (en) 2016-10-11

Similar Documents

Publication Publication Date Title
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
ES2637265T3 (es) Derivados peptídicos, su preparación y sus usos como vectores
ES2729051T3 (es) Agentes terapéuticos para reducir los niveles de hormona paratiroidea
ES2525649T3 (es) Derivados peptídicos y su uso como vectores de moléculas en forma de conjugados
ES2825076T3 (es) Composiciones farmacéuticas
ES2669190T3 (es) Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
ES2259834T3 (es) Peptidos que contienen lisina para el tratamiento de la enfermedad coronaria.
ES2644554T3 (es) Péptidos cíclicos con actividad antiangiogénica y antineoplásica
ES3057215T3 (en) Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
KR20150067228A (ko) 뇌 병태의 치료에서의 안지오텐신
US11083773B2 (en) Peptides that block leukocyte recruitment and methods of use
ES2264279T3 (es) Analogos antagonistas de gh-rh que inhiben igf-i e igf-ii.
ES3019509T3 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
AU2019386379A1 (en) DPEP-1 binding agents and methods of use
ES2965807T3 (es) Combinación de temozolomida y un conjugado de PAR-1 para tratar el glioblastoma
WO2007109609A2 (en) Method for inhibiting angiogenesis
US9737622B2 (en) Compounds modulators of VEGF activity and uses thereof
KR20160065969A (ko) 신규 펩티드 조성물
US9408888B2 (en) High affinity bivalent helically constrained peptide against cancer
US6630120B1 (en) Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors